Equities Analysts Set Expectations for ACAD Q2 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Stock analysts at HC Wainwright dropped their Q2 2025 earnings per share estimates for shares of ACADIA Pharmaceuticals in a research report issued to clients and investors on Thursday, May 8th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings per share of $0.11 for the quarter, down from their previous estimate of $0.16. HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ Q3 2025 earnings at $0.17 EPS, Q4 2025 earnings at $0.21 EPS, FY2025 earnings at $0.61 EPS, FY2026 earnings at $1.86 EPS and FY2029 earnings at $2.33 EPS.

ACAD has been the subject of several other reports. Morgan Stanley reaffirmed an “equal weight” rating and set a $20.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Friday, March 7th. StockNews.com raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Tuesday, April 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 price objective for the company. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $24.70.

ACADIA Pharmaceuticals Trading Up 3.0 %

ACAD stock opened at $17.44 on Friday. ACADIA Pharmaceuticals has a twelve month low of $13.40 and a twelve month high of $20.68. The company has a market capitalization of $2.92 billion, a P/E ratio of 22.36 and a beta of 0.47. The business has a 50 day simple moving average of $15.83 and a 200-day simple moving average of $16.96.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $0.01. The business had revenue of $244.32 million for the quarter, compared to the consensus estimate of $239.32 million. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The business’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.10 EPS.

Insider Activity at ACADIA Pharmaceuticals

In other news, Director Elizabeth A. Garofalo sold 4,919 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the transaction, the director now owns 17,595 shares in the company, valued at approximately $320,756.85. This trade represents a 21.85 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Mark C. Schneyer sold 3,171 shares of the stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $17.05, for a total transaction of $54,065.55. Following the sale, the executive vice president now directly owns 56,889 shares in the company, valued at $969,957.45. This trade represents a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,994 shares of company stock valued at $313,131. Insiders own 26.50% of the company’s stock.

Institutional Trading of ACADIA Pharmaceuticals

Several hedge funds have recently bought and sold shares of ACAD. Vanguard Group Inc. boosted its position in ACADIA Pharmaceuticals by 9.0% during the 1st quarter. Vanguard Group Inc. now owns 15,203,234 shares of the biopharmaceutical company’s stock worth $252,526,000 after acquiring an additional 1,255,594 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of ACADIA Pharmaceuticals during the first quarter valued at approximately $60,845,000. First Trust Advisors LP boosted its position in shares of ACADIA Pharmaceuticals by 27.0% in the fourth quarter. First Trust Advisors LP now owns 2,700,125 shares of the biopharmaceutical company’s stock worth $49,547,000 after buying an additional 574,251 shares during the period. SG Americas Securities LLC boosted its position in ACADIA Pharmaceuticals by 380.3% during the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock worth $45,576,000 after acquiring an additional 1,966,607 shares during the period. Finally, Point72 Asset Management L.P. acquired a new position in ACADIA Pharmaceuticals in the 4th quarter valued at approximately $40,935,000. 96.71% of the stock is currently owned by institutional investors.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.